Drug May Repair DNA at Earliest Stages of Alzheimer’s – And it’s Already Passed Safety Trials
www.goodnewsnetwork.org/drug-may-repair-dna-at-earliest-stages-of-alzheimers-and-its-already-passed-safety-trials/
Replying to @sanitation@lemmy.today
This is a mouse model.
I have no idea what is going on at KC London, but they are running to the press with “cures” every month.
Replying to @SaveTheTuaHawk@lemmy.ca
pmc.ncbi.nlm.nih.gov/articles/PMC10835503/
Safety testing on humans (P1) is complete. No efficacy measures in the study, but that’s not out of the norm for P1.
PubMed Central (PMC)Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL‐286, a novel retinoic acid receptor‐β agonist for treatment of spinal cord injury, in male healthy participantsKCL‐286 is an orally available agonist that activates the retinoic acid receptor (RAR) β2, a transcription factor which stimulates axonal outgrowth. The investigational medicinal product is being developed for treatment of spinal cord injury (SCI). ...